Skip to main content

Table 1 CTL induction from PBMCs of oral cancer patients

From: Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients

      

CTL induction

Survivin

Case no.

age

sex

stage

Origin, histology

Prior treatment

2B80-88 specific CTL

Survivin-C58-specific CTL

expression

#1

63

M

Stage II

buccal mucosa, SCC, well

Chem, Surg

-

+

+

#2

69

M

Stage I

tongue, SCC, basaloid

Surg

-

-

+

#3

60

F

Stage II

mandibular, SCC, m

Chem, Surg

-

-

+

#4

60

M

Stage III

oropharynx, SCC, mod

Chem, Surg

+

-

+

#5

50

F

Stage II

tongue, SCC, well

Chem, Surg

+

+

+

#6

83

F

Stage IVA

maxillary gingiva, SCC, well

Chem, Surg

-

-

+

#7

64

M

Stage II

tongue, SCC, well

Chem, Surg

+

n.d.

+

#8

50

F

Stage II

submaxillary gland, Adenoid cystic

Chem, Surg

-

-

+

#9

65

F

Stage I

tongue, SCC, well

Surg

-

-

+

#10

66

F

Stage II

tongue, SCC, mod

Chem, Surg

+

-

+

#11

73

F

Stage I

tongue, SCC, well

Surg

-

-

+

#12

50

F

Stage I

tongue, SCC, well

Surg

-

-

+

#13

67

M

Stage IVA

oral floor, SCC, poorly

Chem, Surg

n.d.

+

+

H#1

35

M

-

healthy volunteer

-

-

-

Â